益气固表丸对低去脂肪指数慢性阻塞性肺疾病患者微小RNA的影响  

Effects of Yiqi Gubiao Pills on Expressions of miRNA of Low FFMI COPD Patients

作　　者：金晶[1,2] 李风森 李争[2,3] 徐丹 荆晶[2,3] 王晶 JIN Jing;LI Fengsen;LI Zheng;XU Dan;JING Jing;WANG Jing(Xinjiang Medical University,Urumqi 830054,China;Affiliated hospital of Traditional Chinese Medicine of Xinjiang Medical University,Urumqi 830000,China;Key laboratory of respiratory diseases,Xinjiang Uygur Autonomous Region,Urumqi 830000,China)

机构地区：[1]新疆医科大学,新疆乌鲁木齐830054 [2]新疆医科大学附属中医医院,新疆乌鲁木齐830000 [3]新疆维吾尔自治区呼吸病研究重点实验室,新疆乌鲁木齐830000

出　　处：《中国中医药信息杂志》2019年第5期16-22,共7页Chinese Journal of Information on Traditional Chinese Medicine

基　　金：新疆维吾尔自治区自然科学基金面上项目(2018D01C194)

摘　　要：目的观察益气固表丸对低去脂肪质量指数(FFMI)慢性阻塞性肺疾病(COPD)稳定期患者微小RNA(miRNA)及肿瘤坏死因子样微弱凋亡诱导因子(TWEAK)水平的影响。方法选择低FFMI COPD稳定期肺脾气虚证患者60例,按随机双盲对照原则将患者分为益气固表丸组和安慰剂组。2组均行西医基础治疗,益气固表丸组予益气固表丸,安慰剂组予安慰剂,均每次10粒,每日3次,口服,连续治疗12周。选择既往否认COPD及肌病病史的同龄志愿者30例为对照组。采用生物电阻抗法检测患者治疗前后FFMI及双手握力(HGS),ELISA检测治疗前后TWEAK水平,采用GO、KEGG分析进行靶基因预测,qRT-PCR验证治疗前后外周血miRNA变化。结果共脱落6例。揭盲后益气固表丸组28例、安慰剂组26例。益气固表丸组ITT数据集总有效率为96.67%(28/30),安慰剂组为86.67%(26/30),2组比较差异有统计学意义(P<0.05)。益气固表丸组治疗后中医症状评分下降(P<0.05),FFMI、HGS无变化,安慰剂组FFMI、HGS下降(P<0.05)。与对照组比较,2组治疗前TWEAK升高(P<0.05),益气固表丸组治疗后TWEAK下降(P<0.05),安慰剂组治疗后TWEAK无明显变化(P>0.05)。通过GO、KEGG富集分析,结合文献查询筛选miR-1-3p、miR-422a、miR-206、miR-145-5p和miR-133b共5个备选基因。qRT-PCR验证后显示,益气固表丸组治疗前miR-422a、miR-145-5p、miR-133b明显下降(P<0.05),治疗后miR-145-5p、miR-133b明显升高(P<0.05)。结论益气固表丸可有效缓解低FFMICOPD稳定期患者临床症状,提高外周血miR-145-5p、miR-133b水平,降低TWEAK水平,减轻患者全身炎症反应。Objective To observe the effects of Yiqi Gubiao Pills on expressions of microRNA(miRNA) and the level of tumor necrofacies-like weak inducer of apoptosis(TWEAK) in chronic obstructive pulmonary disease(COPD) patients with low fat free mass index(FFMI). Methods Totally 60 patients with low FFMI COPD stable lung spleen qi deficiency syndrome were selected, and were divided into Yiqi Gubiao Pills group and placebo group according to randomized double-blind control principle. Both groups received Western medicine basic treatment. Yiqi Gubiao Pills group was given Yiqi Gubiao pills, and placebo group was given placebo, 10 pills each time, three times a day, orally, for 12 weeks. 30 volunteers of the same age who had previously denied the history of COPD and myopathy were selected as control group. The bioelectrical impedance method was used to detect the changes of FFMI and hand grip strength(HGS) before and after treatment. The TWEAK level before and after treatment was detected by ELISA. GO and KEGG analysis was used to predict target genes, and qRT-PCR was used to verify mi RNA changes in peripheral blood before and after treatment. Results Six cases were lost during treatment. 28 cases left in Yiqi Gubiao Pills group, and 26 were left in placebo group. The total effective rate of ITT data set of Yiqi Gubiao Pills group was 96.67%(28/30), and that of placebo group was 86.67%(26/30), with statistical significance(P<0.05). TCM symptom scores decreased after treatment in Yiqi Gubiao Pills group(P<0.05), FFMI and HGS did not change, and FFMI and HGS decreased in placebo group(P<0.05). Compared with the control group, the TWEAK increased in the two groups before treatment(P<0.05), and the TWEAK decreased in Yiqi Gubiao Pills group(P<0.05). There was no significant change in TWEAK in placebo group after treatment(P>0.05). A total of 5 candidate genes for miR-1-3p, miR-422a, miR-206, miR-145-5p and miR-133b were screened by GO and KEGG enrichment analysis. After qRT-PCR verification, miR-422a, miR-145-5p and miR-133b sign

关 键 词：慢性阻塞性肺疾病稳定期 益气固表丸 微小RNA 肿瘤坏死因子样微弱凋亡诱导因子 临床研究 

分 类 号：R259.63[医药卫生—中西医结合]